Organiser:Informa Markets Time:February 4-6, 2025 Address:800 W. Katella Ave., Anaheim, CA 92802, USA Exhibition hall:Anaheim Convention Center Product range: Medical Supplies: Anesthesiology & Respiratory Medications, Home Care Products, Cardiovascular Supplies, Orthopedic Surgical Instruments, Radiology & Medical Imaging, Emergency & Trauma Care, Surgical Instruments, Sports Medicine & Rehabilitation Therapy, In Vitro Diagnostic Equipment, and General Hospital Supplies & Equipment Medical Materials & Components: New Materials, 3D Printing, Robotics & Automation, Silicones, Mobile Power Solutions, Essential Considerations for Avoiding Medical Device Battery Failures, Innovative Medical Devices, Metal 3D Printing, Intelligent Layering, Integrated Product Design & Development Services Medical Devices: Medical Technology Equipment, Laboratory Instrumentation, Medical Electronic Equipment, Medical Diagnostic Equipment, Ophthalmic Equipment & Protective Products, Surgical Instruments, Emergency Response Equipment, Hospital, Dental & Medical Equipment, Dental Service Equipment & Disposable Medical Products, Disposable Medical Products for Hospitals & Homes, Hospital Dentistry, Medical Data Processing Systems, Dental Plastic Surgery, Rehabilitation Equipment, etc. ...
Drugdu.com expert’s response: The naming of in vitro diagnostic reagents must follow a series of clear requirements to ensure the standardization, accuracy, and ease of understanding of the names. These requirements mainly include the following points: Ⅰ. Naming Structure The product name of in vitro diagnostic reagents typically consists of three parts: Name of the Substance Being Tested: This is the target substance that the reagent detects, and the name should accurately reflect the characteristics of the substance being tested. Purpose: Describes the purpose of the reagent, such as “assay kit,” “quality control material,” etc. This part helps users understand the specific application of the reagent. Method or Principle: Explains the method or principle of the reagent’s detection, such as “magnetic bead-based chemiluminescent immunoassay,” “fluorescent PCR method,” “fluorescent in situ hybridization,” etc. This information is usually listed in parentheses to provide additional technical details. Ⅱ. Specific Naming Rules Quantitative vs. Qualitative ...
A report released by the World Health Organization in 2017 mentioned that about 322 million people suffer from depression worldwide; according to the “2022 National Depression Blue Book”, the number of people suffering from depression in my country is as high as 95 million, but the treatment rate is only 9.5%. As social pressure increases, more and more people have mental health problems, the number of patients with depression continues to increase, and the demand for antidepressants continues to increase. According to Grand View Research, the global antidepressant market size will reach US$60 billion in 2028. At present, although there are many antidepressants available clinically, most drugs still have defects such as slow onset, low efficiency, and even sexual dysfunction and cognitive impairment. Therefore, patients still need more new and effective antidepressants. LPM682000012 is a Class 1 new drug declared by Luye Pharmaceuticals. The indication for clinical trials approved this ...
Recently, Johnson & Johnson announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for its Varipulse pulsed field ablation system for the treatment of drug-refractory paroxysmal atrial fibrillation. After obtaining approval, Johnson & Johnson became the third company in the United States to have PFA technology for the treatment of AFib, joining the ranks of Medtronic and Boston Scientific, and the three-way competition in the PFA market has officially begun. It is understood that the Varipulse pulsed field ablation system consists of the Varipulse ablation catheter and the TRUPULSE generator. Among them, the VARIPULSE ablation catheter was developed based on Johnson & Johnson’s previous mapping catheter LASSO catheter, which is a continuation of the LASSO catheter technology, which further demonstrates Johnson & Johnson’s deep technical reserves in the catheter field. The Varipulse ablation catheter has 10 electrodes on the ring tip, and the ring tip ...
Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has been severely warned by shareholders due to poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared: If the company’s performance cannot be improved, Deepak Nath will be dismissed, and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and advanced wound management. At present, Smith & Nephew ...
On the evening of November 12, BeiGene released its 2024 third quarter US stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continued to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. The US stock financial report shows that BeiGene’s financial situation continues to improve, with total revenue of US$1.002 billion this ...
In 2024, 207 varieties passed/are deemed to have passed the consistency evaluation in October, involving 203 companies (counted as group companies), of which 47 companies passed multiple varieties, and Zhengda Tianqing Pharmaceutical Group Co., Ltd. had the largest number of varieties passed. Chiatai Tianqing ranked first in the “number of varieties passed by the company” 1. Overall situation In October, a total of 207 varieties passed/are deemed to have passed the consistency evaluation: 151 varieties were deemed to have passed the consistency evaluation when they were launched as newly registered classified generic drugs; 59 varieties passed the evaluation with supplementary applications for generic drug consistency evaluation, an increase of 20 varieties compared to September. According to the statistics of the approval documents for marketed drugs, 12 varieties were launched in October as newly registered classified generic drugs, and the first was deemed to have passed the consistency evaluation, and 3 ...
According to the CDE official website, two new traditional Chinese medicines have obtained implicit permission for clinical trials. They are the Category 2.3 new drug “Xuesaitong Soft Capsules” from China Resources Shenghuo and the Category 1.1 new drug “Jiuwei Zhengxiao” from the Institute of Clinical Basic Medicine of the China Academy of Chinese Medical Sciences. Particles”. Xuesaitong soft capsule: carotid atherosclerosis Xuesaitong soft capsule has the functions of activating blood circulation, removing blood stasis, unblocking meridians and activating meridians, and its main component is total saponins of Panax notoginseng. Currently, this drug has been approved for use in the meridian recovery period of ischemic stroke (cerebral infarction) caused by blood stasis blockage. Symptoms include hemiplegia, numbness on one side of the body, crooked mouth and tongue, and slurred speech. This time, China Resources Shenghuo’s Class 2.3 new Chinese medicine “Xuesetong Soft Capsule” has obtained another implied clinical trial license, which ...
Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has received a severe warning from shareholders due to its poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared that if the company’s performance cannot be improved, Deepak Nath will be dismissed and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not yet “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Century-old enterprise faces crisis Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and ...
On the evening of November 12, BeiGene released its third quarter 2024 U.S. stock performance report and A-share main financial data announcement. In the third quarter, BeiGene continued its strong growth momentum, achieving revenue of 7.139 billion yuan, a year-on-year increase of 26.9%. Global product revenue reached 7.079 billion yuan, a year-on-year increase of 65.1%. The overall performance is eye-catching . In the first three quarters of 2024, BeiGene’s total operating revenue reached 19.136 billion yuan, a year-on-year increase of 48.6%. Products continue to increase in volume at a high speed, with product revenue of 18.986 billion yuan in the first three quarters, a year-on-year increase of 72.9%. Whether it is total revenue or product revenue, the first three quarters have exceeded last year’s full-year revenue of 17.423 billion yuan, and the performance is very eye-catching. According to the U.S. stock financial report, BeiGene’s financial situation continues to improve, with ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.